Abbott Laboratories (BVMF:ABTT34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 978.88B -29.4% |
| Revenue (ttm) | 244.16B +5.7% |
| Net Income | 35.80B -51.3% |
| EPS | 20.49 -51.3% |
| Shares Out | n/a |
| PE Ratio | 27.34 |
| Forward PE | 18.66 |
| Dividend | 0.73 (1.54%) |
| Ex-Dividend Date | Jan 14, 2026 |
| Volume | 138 |
| Average Volume | 424 |
| Open | 47.64 |
| Previous Close | 47.36 |
| Day's Range | 47.64 - 47.64 |
| 52-Week Range | 45.71 - 65.52 |
| Beta | 0.74 |
| RSI | 42.58 |
| Earnings Date | Apr 15, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions...
DGI For The DIY: 2025 Dividend Portfolio Review
2025 saw heightened volatility amid political change, global tariffs, inflation fears, and ongoing geopolitical conflicts. Despite macro headwinds, equity markets advanced, propelled by AI sector enth...
Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit
MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio, one of the world's leading innovative agtech companies, will be taking the stage at the World Agri-Tech Innovation Summit taking place March 16–18, 2026. Chris...
Invesco Rising Dividends Fund Q4 2025 Portfolio Activity
Linde was purchased due to its essential and resilient business model, anchored by long-term contracts and leadership in industrial gases. We sold Oracle due to concerns about downside risk as its inv...
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 Improve...
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliv...
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects
Exact Sciences Stockholders Approve Acquisition by Abbott
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted t...
Abbott declares 409th consecutive quarterly dividend
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/23...
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit...
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) Sys...
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $...
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend...
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy
Abbott Laboratories is rated 'Buy,' following a recent price drop, driven by Nutrition segment weakness and COVID-19 diagnostics decline. ABT's Medical Devices segment, especially CGM, continues to de...
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity
Abbott Laboratories experienced a post-earnings sell-off driven by weakness in its Nutrition segment and a sizable revenue miss. Despite segment headwinds, ABT delivered double-digit bottom-line growt...
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Abbott Laboratories: Buy This Dividend King On Sale Now
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, po...
Abbott faces India scrutiny in cough syrup abuse investigation, documents show
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
Abbott Laboratories Raised Prices, Prompting Sales Slump
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.